© 2006 The Royal College of Psychiatrists
Correspondence |
Initial rate of improvement in major depression
Department of Psychiatry, St Lucas Andreas Hospital, Jan Tooropstraat 164, NL-1006 AE, Amsterdam, The Netherlands. Email: vergouwen{at}slaz.nl
EDITED BY KIRIAKOS XENITIDIS and COLIN CAMPBELL
Dr Mitchell (2006) suggests that it may be pertinent to re-examine another commonly quoted recommendation - that an antidepressant trial must be at least 6 to 8 weeks before switching drugs. The evidence on which switch guidelines are based is weak but these guidelines are applied frequently in daily clinical practice. In previous studies symptom improvement at earlier time points in relation to response has been investigated (e.g. Koran et al, 1995) but the ultimate goal of depression treatment is complete remission. Remission takes longer than 4-6 weeks to achieve but substantial improvement is unlikely after 10-12 weeks (Trivedi et al, 2006). Quitkin et al (2003) investigated the relationship between initial change in symptoms and remission by week 12 and demonstrated that even when there was no improvement after 6 weeks of treatment, an antidepressant trial should be continued because the proportion of patients attaining remission by week 12 was still considerable (i.e. greater than 30%). They argued that a switch of antidepressant medication would be unlikely to have resulted in higher remission rates. Furthermore, large studies are required in which change in symptoms is frequently measured at uniform time-points and dimensions other than those measured by conventional questionnaires for depression are assessed. These might be more sensitive to early change following the initiation of antidepressant treatment (Harmer et al, 2004), and therefore might better predict which patients will attain remission. Calculation of the sensitivity, specificity, area under the receiver operating characteristic curve, and positive and negative predictive power to assess the likelihood of remission for various levels of symptom change at different time-points would help clinicians to decide on clinical applicability. Results from such studies will improve the evidence on which switch guidelines are based.
REFERENCES
- Harmer, C. J., Shelley, N. C., Cowen, P. J., et al
(2004) Increased positive versus negative perception and
memory in healthy volunteers following selective serotonin and norepinephrine
reuptake inhibition. American Journal of Psychiatry,
161, 1256
-1263.
[Abstract/Free Full Text] - Koran, L. M., Hamilton, S. H., Hertzmar, M., et al (1995) Predicting response to fluoxetine in geriatric patients with major depression. Journal of Clinical Psychopharmacology, 15, 421 -427.[CrossRef][Medline]
- Mitchell, A. J. (2006) Two-week delay in onset
of action of antidepressants: new evidence. British Journal of
Psychiatry, 188, 105
-106.
[Abstract/Free Full Text] - Quitkin, F. M., Petkova, E., McGrath, P. J., et al
(2003) When should a trial of fluoxetine for major depression
be declared failed? American Journal of Psychiatry,
160, 734
-740.
[Abstract/Free Full Text] - Trivedi, M. H., Rush, J., Wisniewski, S. R., et al
(2006) Evaluation of outcomes with citalopram for depression
using measurement-based care in STAR*D: implications for clinical
practice. American Journal of Psychiatry,
163, 28-40.
[Abstract/Free Full Text]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||